Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibodies in Drug Discovery

Stefan Weigand's Biography

Stefan Weigand, Head of Large Molecule Research, F. Hoffmann-La Roche Ltd

Stefan became Global Head of Large Molecule Research at Roche pRED in early 2015, overseeing all of Roche’s efforts to discover, design, develop and deliver protein-based medicines. He was previously Head of Biochemical & Analytic Research within the same division. In that role he was responsible for tailored, phase-dependent analytical and biochemical support for all large molecule research projects.
Stefan joined Roche in 2005, holding several positions in oncology research. Among other tasks, he was responsible for the identification of novel technologies, collaboration partners, targets and biologics.
He was appointed Department Head Discovery Oncology in 2010, and led a group of over 50 scientists focused on tumor-host cell interactions. Stefan’s team covered all research activities from target discovery to clinical development for two therapeutic areas: angiogenesis and inflammatory Tumor Micro Environment (iTME).
Before joining Roche, Stefan worked for Bayer, where he moved five compounds into clinical development.
Stefan was a post-doctoral fellow at Stanford University and received his PhD in organic chemistry from the Georg-August University, Göttingen.

Stefan Weigand Image

Roche's Approach to Discover, Design, Develop and Deliver Next Generation Protein Therapeutics

Tuesday, 9 February 2016 at 11:45

Add to Calendar ▼2016-02-09 11:45:002016-02-09 12:45:00Europe/LondonRoche's Approach to Discover, Design, Develop and Deliver Next Generation Protein TherapeuticsAntibodies in Drug Discovery in Cambridge, UKCambridge,

My presentation will start with a problem statement regarding complexity of disease, pick up on diversity generation during binder generation, selection of best format (like bi-specifics, small-large molecule combos, brain-shuttle molecules) during LO phase, and end with showcasing that complex biologics can be produced for clinic with similar efficiency as IgGs - given the right set-up.

Add to Calendar ▼2016-02-09 00:00:002016-02-10 00:00:00Europe/LondonAntibodies in Drug DiscoveryAntibodies in Drug Discovery in Cambridge, UKCambridge,